CarlaMarie(Lichtenberger)NesterMDMSA, FASN
Nephrology • Iowa City, IAProfessor of Internal Medicine and Pediatrics, University Iowa,Carver College of Medicine
Dr. Nester is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
285 Newton Road
5294 CBRB
Iowa City, IA 52241Phone+1 319-335-2214Fax+1 319-384-9616
Education & Training
University of North Carolina HospitalsFellowship, Nephrology, 2003 - 2007- University of North Carolina HospitalsFellowship, Pediatric Nephrology, 2003 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine/Pediatrics, 1998 - 2002
Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
IA State Medical License 2007 - 2025
NC State Medical License 1999 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Nephrology
Publications & Presentations
PubMed
- 656 citationsKDIGO 2021 Clinical Practice Guideline for the Management of Glomerular DiseasesBrad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge
Kidney International. 2021-10-01 - 348 citationsExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge
Kidney International. 2021-10-01 - 30 citationsClinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN StudyDavid T. Selewski, Josephine M. Ambruzs, Gerald B. Appel, Andrew S. Bomback, Raed Bou Matar
Kidney International Reports. 2018-08-03
Press Mentions
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNOctober 26th, 2024- Novartis Oral Fabhalta® (Iptacopan) Sustained Clinically Meaningful Results at One Year in Phase III C3 Glomerulopathy (C3G) TrialOctober 26th, 2024
- Pivotal VALIANT Results Presented at Kidney Week Show Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGNOctober 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
